share_log

Goldman Sachs Maintains Buy on Prometheus Biosciences, Raises Price Target to $144

Benzinga Real-time News ·  Jan 31, 2023 09:23

Goldman Sachs analyst Chris Shibutani maintains Prometheus Biosciences (NASDAQ:RXDX) with a Buy and raises the price target from $117 to $144.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment